HALT PKD 试验中不同变异类型和分子结构域的 ADPKD 进展
本研究基于 HALT A 临床试验中 332 例早期常染色体显性多囊肾病(ADPKD)患者,分析 PKD1 变异位置对疾病进展的影响。结果显示,PKD1 截短变异与非截短变异总体进展相似,但非截短变异位于受体卵胶质域和 polycystin-1、脂氧合酶、α-毒素域者 htTKV 年增长显著快于位于 C 型凝集素域和多囊肾病重复域者(P < 0.001)。
要点
- PKD1 非截短变异的结构域位置可预测早期 ADPKD 的 htTKV 增长。
- 受体卵胶质域和 polycystin-1、脂氧合酶、α-毒素域变异者 htTKV 增长较快。
- C 型凝集素域和多囊肾病重复域变异者 htTKV 增长较慢。
核心结论
- PKD1 非截短变异的结构域位置应作为早期 ADPKD 进展的潜在预后标志物进一步探索。
研究设计与样本
- 基于 HALT A 临床试验数据集,纳入 332 例早期 ADPKD 患者,分析纵向身高校正总肾脏体积(htTKV)、eGFR 和 Mayo 影像分类(MIC)分布。
- HALT A 对每例患者的致病变异进行了 Sanger 测序确认。
- 按位置将截短变异(n=222)和非截短变异(n=110)分配至 polycystin-1 关键功能域。
- 比较截短与非截短状态以及 PKD1 变异蛋白结构域位置对纵向 htTKV、eGFR 轨迹和 MIC 分布的影响。
主要发现
- PKD1 截短变异与非截短变异总体疾病进展相似,截短变异不同结构域位置间疾病严重程度无差异。
- PKD1 非截短变异位于受体卵胶质域者 htTKV 年增长 8.6%(95%CI 6.9–10.2),位于 polycystin-1、脂氧合酶、α-毒素域者年增长 8.5%(95%CI 5.9–11.2)。
- 上述两个结构域变异者的 htTKV 增长显著高于 C 型凝集素域(年增长 3.6%,95%CI 1.1–6.1)和多囊肾病重复域(年增长 4.4%,95%CI 2.3–6.5)者(P < 0.001)。
- 快进展与慢进展区域的变异在 MIC 分布上差异有临床意义(P = 0.008)。
- eGFR 变化率在快进展与慢进展区域间为 −3.51 对 −2.24 ml/min/年(P = 0.09)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Patients with autosomal dominant polycystic kidney disease (ADPKD) experience substantial variation in disease progression. The location of pathogenic nontruncating variants in PKD1 significantly predicts disease progression in patients with early-stage ADPKD. Pathogenic variant location in PKD1 merits further exploration in determining prognosis in patients with ADPKD. BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of ESKD. Disease severity depends on the causative gene (PKD1 versus PKD2) and whether its pathogenic variant is truncating or nontruncating. However, the association between ADPKD severity and the location of pathogenic variants is controversial. An emerging understanding of the functional domains of the PKD genes may enable further investigation of the impact of variant location on disease severity. METHODS: We studied longitudinal height-adjusted total kidney volume (htTKV), eGFR, and Mayo Imaging Classification (MIC) distributions among a cohort of 332 patients with early-stage ADPKD in the HALT A clinical trial dataset to examine the impact of PKD1 variant location on disease progression. HALT A provided Sanger sequencing confirmation for each patient's pathogenic variant. Truncating (n=222) and nontruncating genetic variants (n=110) were assigned by location to key polycystin-1 functional domains. We compared patients' longitudinal htTKV and eGFR trajectories and MIC distributions for truncating versus nontruncating status and the protein domain location of PKD1 variants. RESULTS: PKD1 truncating variants demonstrated similar disease progression to PKD1 nontruncating variants overall, and disease severity did not differ by domain location for truncating variants. However, patients with PKD1 nontruncating variants in the receptor egg jelly (8.6% per year; 95% confidence interval [6.9 to 10.2]) and polycystin-1, lipoxygenase, α-toxin domain (8.5% per year [5.9 to 11.2]) domains demonstrated significantly greater htTKV growth compared with PKD1 nontruncating variants in the C-type lectin (3.6% per year [1.1 to 6.1]) and polycystic kidney disease repeat (4.4% per year [2.3 to 6.5]) domains (P < 0.001). Variants in these fast- and slow-progressing regions also showed clinically significant differences in MIC distribution (P = 0.008) and eGFR rate of change (−3.51 versus −2.24 ml/min per year; P = 0.09). CONCLUSIONS: Our findings demonstrate that the domain locations of nontruncating variants in PKD1 should be explored as potential prognostic markers of early-stage ADPKD progression. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: NCT00283686.
引用
- Sucholeiki RL, Jochum E, Chen P, et al. ADPKD Progression by Variant Type and Molecular Domain Among Participants in the HALT PKD Trial. Clin J Am Soc Nephrol. 2025. PMID: 40762980. doi:10.2215/CJN.0000000801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。